Portage Biotech Inc. PRTG
At closeSep 3, 2025, 4:00 PM EDT
52-week range unavailable
- Market cap
- 15.52M
- Shares out
- 1.12M
- Forward P/E
- -10.37
- Volume
- 371.67K
- Open
- 7.60
- Previous close
- 6.81
- Day's range
- 6.81 – 7.60
- Beta
- 99.48
- Earnings date
- Aug 27, 2024
Key statistics
- Enterprise value
- 417.30K
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.34M
- Total cash
- 3.33M
- Total debt
- 37.00K
- Return on equity
- -191.03%
- Short % of float
- 1.42%
- 50-day average
- 5.09
- 200-day average
- 5.60
Next earnings
Aug 27, 2024
Expected Aug 27, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 26, 2024 | Sep 1, 2024 | 0.00 | -1.26 | — | — |
| Aug 27, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 27, 2024 | Jun 1, 2024 | 0.00 | -1.58 | — | — |
| Aug 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Aug 15, 2024 | Mar 1, 2024 | 0.00 | -24.20 | — | — |
| Feb 28, 2024 | Dec 1, 2023 | -5.40 | -3.60 | +1.80 | +33.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 8, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 29, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 7, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 31, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 2, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 1, 2023 | Cantor Fitzgerald | main | Overweight | Overweight |
About Portage Biotech Inc.
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- British Virgin Islands
- Website
- portagebiotech.com
News
12 Health Care Stocks Moving In Wednesday's Intraday Session 
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem 
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements 
Portage Biotech and Compedica Stock-for-Stock Exchange 
Portage Biotech Stock Surges As It Prepares For Human Trial
Your note
Sign in to keep a note on PRTG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Mintz (Steven Michael) | Director of Issuer | Acquisition or disposition in the public market | Mar 6, 2022 | 24,493 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bison Wealth, LLC | 9.39% | 98,521 | 531.03K | Sep 29, 2024 |
| Virtu Financial LLC | 1.04% | 10,919 | 58.85K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.96% | 10,058 | 54.21K | Sep 29, 2024 |
| Connective Capital Management LLC | 0.75% | 7,909 | 42.63K | Sep 29, 2024 |
| UBS Group AG | 0.24% | 2,466 | 13.29K | Sep 29, 2024 |
| Blackrock Inc. | 0.04% | 408 | 2.20K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 107 | 576 | Oct 30, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 1 | 5 | Aug 30, 2024 |